Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head Shi Wang on July 31, with his successor undisclosed. Meanwhile, French major Sanofi revealed that Shi Wang will take the helm of Sanofi Greater China as president and general medicine head as of August 1, when the incumbent Pius S. Hornstein will be transferred to Paris to take charge of global digital business.
Shi Wang’s Background
Shi Wang graduated from the Nanjing University of Chinese Medicine with a bachelor’s degree in traditional Chinese medicine and obtained an MBA from the Olin School of Business of Washington University. He is a pharmaceutical veteran, having served as general manager of AstraZeneca Hong Kong, as well as vice president of cardiovascular business, director of global product portfolios, and managing director and head of regional operations of Merck China, among other roles.
Tenure at Organon
Shi Wang took up his post as Organon China in August 2020, when the company split from Merck, Sharp & Dohme (MSD; NYSE: MRK). His leadership and expertise have contributed significantly to Organon’s growth in the Chinese market.-Fineline Info & Tech
